Another clinical trial is investigating PF-04518600, an OX40 agonist, alone or in combination with the 4-1BB (CD137) agonist PF-05082566 (NCT02315066) in patients with select advanced or metastatic carcinoma including HNSCC. This evidence concerns the gene TNFRSF9 and head and neck squamous cell carcinoma.